YD Bio Ltd

YD Bio Ltd

YDES · NASDAQ · Healthcare / Biotechnology

4.88USD-0.32 (-6.06%)

Price History

Full chart

Market Stats

Previous Close5.20
Open5.08
Day Range4.88 – 5.45
52-Week Range1.70 – 22.00
Volume24.88K
Market Cap539.03M
P/E (TTM)0.00
Forward P/E0.00
EPS0.00
Dividend Yield0.00%
Beta-0.03
50-Day Avg3.50
200-Day Avg6.21

About

YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma. It also provides Hydrogel (Hioxifilcon A) Soft (Hydrophilic) Contact Lens, a spherical and aspherical lenses. In addition, the company supplies drugs and medical materials for clinical trials; and operates DNA methylation-based oncology testing programs. Further, it provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination, and compliance-focused support for clinical development programs to pharmaceutical and biotechnology companies. It serves corporate and retail customers. The company was founded in 2013 and is based in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Ethan Shen Ph.D.
  • Employees13
  • HeadquartersNo. 3, Xingnan St., Taipei, Taiwan, 115001, USA
  • Websitehttps://www.ydesgroup.com

Leadership

  • Dr. Ethan Shen Ph.D.CEO & Chairman · b. 1977
  • Dr. Benjamin Zhang M.D.Chief Medical Officer & Director · b. 2000

Financials

Income Statement

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---350.13K510.36K596.82K
Growth (%)----+45.76%+16.94%
Cost of Revenue---196.69K355.00K638.97K
Gross Profit---153.44K155.36K-42.15K
Gross Margin---43.83%30.44%-7.06%
Operating Expense---163.29K1.62M5.23M
Operating Income-344.22K-1.72M-2.32M-9.85K-1.46M-5.27M
Operating Margin----2.81%-286.45%-883.31%
EBITDA-2.54M8.70M3.79M22.25K-1.28M-8.10M
EBITDA Margin---6.35%-250.99%-1357.75%
Net Income-2.54M8.70M3.79M13.56K-1.41M-8.31M
Net Income Margin---3.87%-276.58%-1392.61%
R&D---0491.35K1.60M
R&D as % of Total Revenue---0.00%96.28%268.43%
Interest Expense---2.14K7720
Interest Expense % of Total Revenue---0.61%0.15%0.00%

Balance Sheet

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets117.59M118.06M17.93M321.21K6.86M13.78M
Total Liabilities17.81M9.11M6.74M298.22K273.98K16.64M
Total Equity99.78M108.96M11.20M22.99K6.59M-2.86M
Cash693.82K5.40K14.13K87.10K3.13M6.01M
Total Debt---47.58K22.55K6.76K
Net Debt-693.82K-5.40K-14.13K-39.52K-3.11M-6.00M

Cash Flow

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-253.63K-688.41K-3.02M-55.66K-1.84M-6.60M
Investing Cash Flow-116.72M-1.15M100.38M-290-2.90M-1.44M
Financing Cash Flow117.67M1.15M-97.34M113.89K7.73M10.87M
Capital Expenditure5502902.91M1.44M
Free Cash Flow-253.62K-688.42K-3.02M-55.95K-4.75M-8.04M
FCF to OCF100.00%100.00%100.00%100.52%258.48%121.83%

Earnings

Report DateDec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Nov 25, 2024Dec 31, 2024Apr 30, 2025Jun 30, 2025
EPS Estimate-------------------
EPS Actual-0.170.40-0.110.220.090.180.080.20-0.22-0.14-0.35-0.250.16-5.124.05-0.160.10-1.10-0.65
Surprise-------------------
Timing-------------------

Key Statistics & Ratios

Market Cap539.03M
Enterprise Value226.17M
Trailing P/E0.00
Forward P/E0.00
Price / Sales434.94
Price / Book51.15
EPS0.00
Book Value4.57
Revenue (TTM)1.24M
Gross Profit (TTM)366.85K
EBITDA-6.34M
Profit Margin24.67%
Operating Margin-382.12%
Return on Equity-42.69%
Return on Assets-25.43%
Shares Outstanding70.83M
Shares Float15.80M
Beta-0.03
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
0.40%
Insiders
80.15%
Retail / Other
19.45%

Top Institutional Holders

  • Garrett Wealth Advisory Group, LLC
    84.63K0.12%
  • Geode Capital Management, LLC
    60.24K0.09%
  • Cypress Capital Management, LLC
    33.69K0.05%
  • HPM Partners LLC
    32.41K0.05%
  • Citadel Advisors Llc
    30.11K0.04%
  • UBS Group AG
    11.63K0.02%
  • Wolverine Asset Management LLC
    4.89K0.01%
  • Morgan Stanley - Brokerage Accounts
    2230.00%
  • FMR Inc
    10.00%
  • Citigroup Inc
    00.00%
  • Bank of America Corp
    00.00%

Top Fund Holders

  • Fidelity Nasdaq Composite Index
    44.94K0.06%
  • Fidelity Nasdaq Composite ETF
    22.86K0.03%
  • Arrow Long/Short Alt Fd F
    21.00K0.03%